QT Prolongation and Safety Pharmacology Informa Life Sciences Swissôtel Le Plaza Switzerland
| Wednesday, June 3, 2009 | ||
| 08:00:00 | Conference registration and morning coffee | |
| 08:30:00 | Opening remarks from the Chairperson | |
| 08:35:00 | Conclusions from a review of ICH S7 guidelines | Gerd Bode |
| 09:05:00 | Overview of recent Q&A with E14 working group and the impacts for your future trial designs | Charles T Benson |
| 09:35:00 | Regulations Q&A | |
| 09:45:00 | Effectively predicting QT prolongation in humans | |
| 10:20:00 | Morning coffee | |
| 11:00:00 | The translatability of existing and emerging preclinical cardiotoxicity assays | Matthew J Killeen |
| 11:35:00 | Stem cells as a tool in preclinical testing for QT prolongation | Martin Traebert |
| 12:10:00 | Spotlight session | |
| 12:45:00 | Lunch | |
| 14:15:00 | Bridging the gap between non-clinical and clinical studies | Wilhelm Haverkamp |
| 14:50:00 | Drug induced QT/QTc prolongation - Review of one-stage vs. two-stage methods to analyse clinical ECG data | Jianguo Li |
| 15:25:00 | Afternoon tea and high speed networking | |
| 16:05:00 | Designing a tQT study for limited resources | Arne Ring |
| 16:40:00 | Methods for reducing variability in QT assessment | Henry Holzgrefe |
| 17:15:00 | Applications of mixed models in tQT studies | Dennis Chanter |
| 17:50:00 | Closing remarks from the Chairperson | |
| 17:55:00 | End of day one | |
| Thursday, June 4, 2009 | ||
| 08:30:00 | Opening remarks from the Chairperson | |
| 08:35:00 | Assessing the risk of proarrythmia? | Danshi Li |
| 09:10:00 | Three years post E14 guidance – Challenges and potential solutions | Sasha Latypova |
| 09:45:00 | Cardiac safety strategies for FIM studies for biopharmaceuticals | Alexander Breidenbach |
| 10:20:00 | Morning coffee and "meet the author" poster session | |
| 11:00:00 | QT study design for oncology drugs | Corina-Dana Dota, |
| 11:30:00 | Unwanted QT problems in oncology programmes - A hERG trafficking case study | Bérengère Dumotier |
| 12:00:00 | Q&A session - What have we learned from oncology QT studies to date? | |
| 12:10:00 | Spotlight session | |
| 12:45:00 | Lunch | |
| 14:10:00 | Drug related change in the ECG - A novel biomarker for cardiac risk? | Christer Gottfridsson |
| 14:45:00 | Optimized Holter extractions in tQT studies | Fabio Badilini |
| 15:20:00 | Afternoon tea | |
| 15:50:00 | Increasing power through developing technologies - 12 lead ECG to continuous recording methods | Corina-Dana Dota, |
| 16:25:00 | Assessing the risk of Na channel inhibition | Danshi Li |
| 17:00:00 | Closing remarks from the Chairperson | |
| 17:10:00 | End of conference | |
How We Rank